NIJMEGEN

New branch office, Nijmegen-Netherlands

Why Netherlands?

The answer is clear.

• The Netherlands alone has a population of around 17.5 million and a high population density of 416 inhabitants/km², making it the fifth most densely populated country in Europe.
• Benelux is known for its strong economy and many key opinion leaders declare this region as an important region for clinical trials.
• The Netherlands has a great deal of knowledge and expertise in the field of drug development.
• More than 400 drug companies, 7 academic hospitals and 14 universities are located within a circle of 200 kilometers.
• The excellent infrastructure, but certainly also the arrival of the European Medicines Agency EMA in Amsterdam, make the Netherlands an attractive location for pharmaceutical companies.
• In the Netherlands, more than 65,000 people are directly and indirectly employed in the pharmaceutical sector.
• There are an estimated 550 new clinical studies per year in the Netherlands, clients could be some of the 2,900 innovative R&D life science companies and 420 biopharmaceutical companies that call the Netherlands their home.